Clinical Trials

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Do you or your child have dyslipidemia? This study is exploring how different diagnostic tests can help us understand how lipid disorders, including high blood cholesterol and high blood triglycerides, affect the body. Information from this study may help improve the way lipid disorders are diagnosed or treated in the future. Participants in this study must be at least 2 years old. The study is being conducted in Bethesda, Maryland.

Are you an adult female with LAM? If so, you may be able to participate in this clinical study where researchers are observing patients who are taking or have taken a certain kind of medication, mammalian target of rapamycin (mTOR), to treat lymphangioleiomyomatosis, also known as LAM. You must be at least 18 years old to take part. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, and Washington.

Have you been diagnosed with LAM? This study is trying to understand the genes and proteins that are responsible for causing lung damage in patients with LAM. To participate in this study, you must be between 16 and 99 years old and diagnosed with LAM. This study is located in Bethesda, Maryland.

Are you an adult female who has been diagnosed with LAM? This study is examining which delivery method of albuterol—inhaled or nebulizer—is better at improving lung function in adult women who have LAM. This study is located in Bethesda, Maryland.

Do you have LAM and would be willing to help research? This study aims to identify the right dose of sirolimus to treat people who have LAM. To participate in this study, you must be female, between 18 and 90 years old, and diagnosed with LAM. This study is located in Bethesda, Maryland.

Do you have tuberous sclerosis and want to help researchers better understand the disease? This study is investigating what causes multiple skin tumors to develop in people with tuberous sclerosis. To participate in the study, you must be at least 18 years old. This study is located at the NIH Clinical Center in Bethesda, Maryland.

Do you have both type II diabetes and obesity? Researchers are studying how exercise and weight-loss affect body fat tissues and cells in the body. Participants must be 18 to 50 years old and be able to do moderately intense physical activity. The study is taking place in Chicago, Illinois.

Are you a black man or women who has obesity and lives in Washington D.C.? This study aims to understand the health and health needs of people in predominately black churches in Washington, D.C. This information will help researchers design programs to improve heart health in these communities. To participate in this study, you must be between 19 and 85 years old and attend one of the churches in the study. This study is based in Bethesda, Maryland.

Are you between 18 and 50 and have obesity? This study is examining whether obesity causes chemical changes to DNA that affect the amounts of certain proteins that your body makes. These changes in protein levels may raise the risk of heart and blood vessel diseases in people who have obesity. The study will test whether regular physical activity and weight loss surgery can help reverse these changes to DNA. This study takes place in Chicago, Illinois.